Expression of ANXA2 in the Extracellular Space in the Microenvironment of Periumoral Edema Promotes Glioma Invasion

NCT04953468 | Unknown

• 1 other identifier: M2021020
• Study Type: observational
• Target: 130
• Locations: 1 country
• Sites: 1

Brief Summary

The prognostic value of ANXA2 expression in tumor tissue and PTBE was analyzed, so as to seek new therapies to inhibit glioma invasion and improve the prognosis of glioma patients

Conditions

Glioma

Keywords

glioma; ANXA2 Expression; periatumoral edema zone

Outcome Measures

Primary Outcomes (1)

• Overall survival

  Follow-up information was collected by telephone follow-up and regular review when patients returned to the hospital. Telephone follow-up was conducted every 3 months, and the main follow-up content was survival time, and the end point of follow-up was to the patient's death

  From the date of surgery to the date of death from any cause, assessed up to 18 weeks.

Study Arms (4)

ANXA2 high expression in glioma

We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion \< 10%, grade 2 for those with staining proportion ≥10% and \< 50%, grade 3 for those with staining proportion ≥50% and \< 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In glioma tissues, samples with expression level ≥6 points were identified as the ANXA2 high expression group

Diagnostic Test: expression level of ANXA2 protein

ANXA2 low expression in glioma

We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion \< 10%, grade 2 for those with staining proportion ≥10% and \< 50%, grade 3 for those with staining proportion ≥50% and \< 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In glioma tissues, samples with expression level \<6 points were identified as the ANXA2 low expression group

Diagnostic Test: expression level of ANXA2 protein

ANXA2 high expression in PTBE

We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion \< 10%, grade 2 for those with staining proportion ≥10% and \< 50%, grade 3 for those with staining proportion ≥50% and \< 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In PTBE, samples with expression level ≥2 were regarded as the ANXA2 high expression group

Diagnostic Test: expression level of ANXA2 protein

ANXA2 low expression in PTBE

We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion \< 10%, grade 2 for those with staining proportion ≥10% and \< 50%, grade 3 for those with staining proportion ≥50% and \< 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In PTBE, samples with expression level \<2 were regarded as the ANXA2 low expression group

Diagnostic Test: expression level of ANXA2 protein

Interventions

expression level of ANXA2 protein DIAGNOSTIC_TEST

The expression level of ANXA2 protein in glioma and PTBE was detected by immunohistochemistry

ANXA2 high expression in PTBE; ANXA2 high expression in glioma; ANXA2 low expression in PTBE; ANXA2 low expression in glioma

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients (aged 18-75 years) who underwent microsurgical resection of glioma in the Neurosurgery Department of Peking University Third Hospital between 2018 and 2020

You may qualify if:

• Patients who have undergone microneurosurgical resection of the tumor in our hospital and are pathologically confirmed to be supratentorial glioma;
• Preserving the remaining tissue samples of paired gliomas and PTBE for pathological examination;
• The patients agreed to be enrolled and signed the informed consent;
• The clinical data of the patients are complete and not lost;
• No serious complications occurred after surgery.

Sponsors & Collaborators

• Peking University Third Hospital: lead

Study Sites (1)

Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Immunohistochemistry of glioma tissue

MeSH Terms

Conditions

Glioma

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Officials

• Yang Jun

  Peking University Third Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yang Jun

CONTACT

13901291211; 13901291211@163.com

Chen Xin

CONTACT

13611061786

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 28, 2021
• First Posted: July 8, 2021
• Study Start: February 19, 2021
• Primary Completion: August 1, 2022
• Study Completion: August 1, 2023
• Last Updated: July 8, 2021

Record last verified: 2021-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)